Search Results For:

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => Array
        (
            [issue] => Array
                (
                    [0] => roles-responsibilities
                )

            [agreement-type] => Array
                (
                    [0] => research-development-agreement
                )

        )

    [filters] => Array
        (
            [provision] => Array
                (
                    [issue] => Array
                        (
                            [0] => roles-responsibilities
                        )

                )

            [agreement] => Array
                (
                    [agreement-type] => Array
                        (
                            [0] => research-development-agreement
                        )

                )

        )

    [child_filters] => Array
        (
        )

    [agreement_args] => Array
        (
            [post_type] => agreement
            [posts_per_page] => -1
            [tax_query] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => agreement-type
                            [field] => slug
                            [terms] => Array
                                (
                                    [0] => research-development-agreement
                                )

                        )

                )

        )

    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [tax_query] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => issue
                            [field] => slug
                            [terms] => Array
                                (
                                    [0] => roles-responsibilities
                                )

                        )

                )

            [meta_query] => Array
                (
                    [relation] => OR
                    [0] => Array
                        (
                            [key] => agreement
                            [value] => "11902"
                            [compare] => LIKE
                        )

                    [1] => Array
                        (
                            [key] => agreement
                            [value] => "5773"
                            [compare] => LIKE
                        )

                    [2] => Array
                        (
                            [key] => agreement
                            [value] => "2438"
                            [compare] => LIKE
                        )

                    [3] => Array
                        (
                            [key] => agreement
                            [value] => "1040"
                            [compare] => LIKE
                        )

                    [4] => Array
                        (
                            [key] => agreement
                            [value] => "3313"
                            [compare] => LIKE
                        )

                    [5] => Array
                        (
                            [key] => agreement
                            [value] => "2882"
                            [compare] => LIKE
                        )

                    [6] => Array
                        (
                            [key] => agreement
                            [value] => "11914"
                            [compare] => LIKE
                        )

                    [7] => Array
                        (
                            [key] => agreement
                            [value] => "3719"
                            [compare] => LIKE
                        )

                    [8] => Array
                        (
                            [key] => agreement
                            [value] => "12939"
                            [compare] => LIKE
                        )

                    [9] => Array
                        (
                            [key] => agreement
                            [value] => "8049"
                            [compare] => LIKE
                        )

                    [10] => Array
                        (
                            [key] => agreement
                            [value] => "994"
                            [compare] => LIKE
                        )

                    [11] => Array
                        (
                            [key] => agreement
                            [value] => "7560"
                            [compare] => LIKE
                        )

                    [12] => Array
                        (
                            [key] => agreement
                            [value] => "1101"
                            [compare] => LIKE
                        )

                    [13] => Array
                        (
                            [key] => agreement
                            [value] => "12042"
                            [compare] => LIKE
                        )

                    [14] => Array
                        (
                            [key] => agreement
                            [value] => "4678"
                            [compare] => LIKE
                        )

                    [15] => Array
                        (
                            [key] => agreement
                            [value] => "4692"
                            [compare] => LIKE
                        )

                    [16] => Array
                        (
                            [key] => agreement
                            [value] => "12977"
                            [compare] => LIKE
                        )

                    [17] => Array
                        (
                            [key] => agreement
                            [value] => "11819"
                            [compare] => LIKE
                        )

                    [18] => Array
                        (
                            [key] => agreement
                            [value] => "3373"
                            [compare] => LIKE
                        )

                    [19] => Array
                        (
                            [key] => agreement
                            [value] => "3333"
                            [compare] => LIKE
                        )

                    [20] => Array
                        (
                            [key] => agreement
                            [value] => "12574"
                            [compare] => LIKE
                        )

                    [21] => Array
                        (
                            [key] => agreement
                            [value] => "5586"
                            [compare] => LIKE
                        )

                    [22] => Array
                        (
                            [key] => agreement
                            [value] => "5589"
                            [compare] => LIKE
                        )

                    [23] => Array
                        (
                            [key] => agreement
                            [value] => "6626"
                            [compare] => LIKE
                        )

                    [24] => Array
                        (
                            [key] => agreement
                            [value] => "11261"
                            [compare] => LIKE
                        )

                    [25] => Array
                        (
                            [key] => agreement
                            [value] => "1392"
                            [compare] => LIKE
                        )

                    [26] => Array
                        (
                            [key] => agreement
                            [value] => "12591"
                            [compare] => LIKE
                        )

                    [27] => Array
                        (
                            [key] => agreement
                            [value] => "1075"
                            [compare] => LIKE
                        )

                    [28] => Array
                        (
                            [key] => agreement
                            [value] => "1077"
                            [compare] => LIKE
                        )

                    [29] => Array
                        (
                            [key] => agreement
                            [value] => "11692"
                            [compare] => LIKE
                        )

                    [30] => Array
                        (
                            [key] => agreement
                            [value] => "12092"
                            [compare] => LIKE
                        )

                    [31] => Array
                        (
                            [key] => agreement
                            [value] => "9058"
                            [compare] => LIKE
                        )

                    [32] => Array
                        (
                            [key] => agreement
                            [value] => "12405"
                            [compare] => LIKE
                        )

                    [33] => Array
                        (
                            [key] => agreement
                            [value] => "9074"
                            [compare] => LIKE
                        )

                    [34] => Array
                        (
                            [key] => agreement
                            [value] => "11016"
                            [compare] => LIKE
                        )

                    [35] => Array
                        (
                            [key] => agreement
                            [value] => "1104"
                            [compare] => LIKE
                        )

                    [36] => Array
                        (
                            [key] => agreement
                            [value] => "7440"
                            [compare] => LIKE
                        )

                    [37] => Array
                        (
                            [key] => agreement
                            [value] => "11109"
                            [compare] => LIKE
                        )

                    [38] => Array
                        (
                            [key] => agreement
                            [value] => "3776"
                            [compare] => LIKE
                        )

                    [39] => Array
                        (
                            [key] => agreement
                            [value] => "2732"
                            [compare] => LIKE
                        )

                    [40] => Array
                        (
                            [key] => agreement
                            [value] => "2455"
                            [compare] => LIKE
                        )

                    [41] => Array
                        (
                            [key] => agreement
                            [value] => "2817"
                            [compare] => LIKE
                        )

                    [42] => Array
                        (
                            [key] => agreement
                            [value] => "12076"
                            [compare] => LIKE
                        )

                    [43] => Array
                        (
                            [key] => agreement
                            [value] => "6274"
                            [compare] => LIKE
                        )

                    [44] => Array
                        (
                            [key] => agreement
                            [value] => "11632"
                            [compare] => LIKE
                        )

                )

        )

    [text_agreement_args] => 
    [text_provision_args] => 
    [agreement_ids] => Array
        (
            [0] => 11902
            [1] => 5773
            [2] => 2438
            [3] => 1040
            [4] => 3313
            [5] => 2882
            [6] => 11914
            [7] => 3719
            [8] => 12939
            [9] => 8049
            [10] => 994
            [11] => 7560
            [12] => 1101
            [13] => 12042
            [14] => 4678
            [15] => 4692
            [16] => 12977
            [17] => 11819
            [18] => 3373
            [19] => 3333
            [20] => 12574
            [21] => 5586
            [22] => 5589
            [23] => 6626
            [24] => 11261
            [25] => 1392
            [26] => 12591
            [27] => 1075
            [28] => 1077
            [29] => 11692
            [30] => 12092
            [31] => 9058
            [32] => 12405
            [33] => 9074
            [34] => 11016
            [35] => 1104
            [36] => 7440
            [37] => 11109
            [38] => 3776
            [39] => 2732
            [40] => 2455
            [41] => 2817
            [42] => 12076
            [43] => 6274
            [44] => 11632
        )

    [agreement_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => agreement-type
                                    [field] => slug
                                    [terms] => Array
                                        (
                                            [0] => research-development-agreement
                                        )

                                )

                        )

                )

            [query_vars] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => agreement-type
                                    [field] => slug
                                    [terms] => Array
                                        (
                                            [0] => research-development-agreement
                                        )

                                )

                        )

                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [s] => 
                    [sentence] => 
                    [title] => 
                    [fields] => all
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [orderby] => title
                    [order] => ASC
                    [ignore_sticky_posts] => 
                    [suppress_filters] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [taxonomy] => agreement-type
                    [term] => research-development-agreement
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => agreement-type
                                    [terms] => Array
                                        (
                                            [0] => research-development-agreement
                                        )

                                    [field] => slug
                                    [operator] => IN
                                    [include_children] => 1
                                )

                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                            [0] => wpry_term_relationships
                        )

                    [queried_terms] => Array
                        (
                            [agreement-type] => Array
                                (
                                    [terms] => Array
                                        (
                                            [0] => research-development-agreement
                                        )

                                    [field] => slug
                                )

                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT   wpry_posts.*
					 FROM wpry_posts  LEFT JOIN wpry_term_relationships ON (wpry_posts.ID = wpry_term_relationships.object_id)
					 WHERE 1=1  AND ( 
  wpry_term_relationships.term_taxonomy_id IN (287)
) AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
					 GROUP BY wpry_posts.ID
					 ORDER BY wpry_posts.post_title ASC
					 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 11902
                            [post_author] => 5
                            [post_date] => 2024-08-26 12:25:26
                            [post_date_gmt] => 2024-08-26 12:25:26
                            [post_content] => 
                            [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-26 12:25:26
                            [post_modified_gmt] => 2024-08-26 12:25:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11902
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 5773
                            [post_author] => 5
                            [post_date] => 2022-09-13 11:54:12
                            [post_date_gmt] => 2022-09-13 11:54:12
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-inc-diagnostics-and-therapeutics-for-viral-infections-global-health-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-13 11:55:56
                            [post_modified_gmt] => 2022-09-13 11:55:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5773
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 2438
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:43:39
                            [post_date_gmt] => 2021-01-19 06:43:39
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:05:25
                            [post_modified_gmt] => 2021-09-15 12:05:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2438
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 1040
                            [post_author] => 6
                            [post_date] => 2020-05-20 21:11:05
                            [post_date_gmt] => 2020-05-20 21:11:05
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-for-profit
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-16 14:22:40
                            [post_modified_gmt] => 2024-07-16 14:22:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1040
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 3313
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:12:41
                            [post_date_gmt] => 2021-06-30 10:12:41
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:03
                            [post_modified_gmt] => 2021-09-15 11:58:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3313
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 2882
                            [post_author] => 6
                            [post_date] => 2021-05-14 14:03:29
                            [post_date_gmt] => 2021-05-14 14:03:29
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:31
                            [post_modified_gmt] => 2021-09-15 11:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2882
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 11914
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:19:40
                            [post_date_gmt] => 2024-09-02 09:19:40
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 09:19:40
                            [post_modified_gmt] => 2024-09-02 09:19:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11914
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 3719
                            [post_author] => 5
                            [post_date] => 2021-08-23 11:02:40
                            [post_date_gmt] => 2021-08-23 11:02:40
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:51
                            [post_modified_gmt] => 2021-09-15 11:58:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3719
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 12939
                            [post_author] => 5
                            [post_date] => 2025-08-18 08:18:21
                            [post_date_gmt] => 2025-08-18 08:18:21
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-18 08:18:32
                            [post_modified_gmt] => 2025-08-18 08:18:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12939
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 8049
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:37:47
                            [post_date_gmt] => 2022-12-12 08:37:47
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-12 08:37:47
                            [post_modified_gmt] => 2022-12-12 08:37:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=8049
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 994
                            [post_author] => 5
                            [post_date] => 2020-05-18 19:52:27
                            [post_date_gmt] => 2020-05-18 19:52:27
                            [post_content] => 
                            [post_title] => CEPI CfP3i Vaccine Funding Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:59:18
                            [post_modified_gmt] => 2021-09-15 11:59:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=994
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 7560
                            [post_author] => 5
                            [post_date] => 2022-12-07 15:07:36
                            [post_date_gmt] => 2022-12-07 15:07:36
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-07 15:08:17
                            [post_modified_gmt] => 2022-12-07 15:08:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=7560
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 1101
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:41:03
                            [post_date_gmt] => 2020-05-21 20:41:03
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-16 14:23:44
                            [post_modified_gmt] => 2024-07-16 14:23:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1101
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 12042
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:36:02
                            [post_date_gmt] => 2024-09-12 12:36:02
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 12:36:02
                            [post_modified_gmt] => 2024-09-12 12:36:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12042
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 4678
                            [post_author] => 5
                            [post_date] => 2022-04-25 11:00:45
                            [post_date_gmt] => 2022-04-25 11:00:45
                            [post_content] => 
                            [post_title] => Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:35:48
                            [post_modified_gmt] => 2022-08-11 09:35:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4678
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 4692
                            [post_author] => 5
                            [post_date] => 2022-04-25 14:24:30
                            [post_date_gmt] => 2022-04-25 14:24:30
                            [post_content] => 
                            [post_title] => Gates Foundation - Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:36:24
                            [post_modified_gmt] => 2022-08-11 09:36:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4692
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 12977
                            [post_author] => 5
                            [post_date] => 2025-08-19 10:12:14
                            [post_date_gmt] => 2025-08-19 10:12:14
                            [post_content] => 
                            [post_title] => Gates Foundation - Atreca, Platform Technology, Program-Related Investment Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-atreca-platform-technology-program-related-investment-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-19 10:12:14
                            [post_modified_gmt] => 2025-08-19 10:12:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12977
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 11819
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:07:00
                            [post_date_gmt] => 2024-07-15 15:07:00
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:07:00
                            [post_modified_gmt] => 2024-07-15 15:07:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11819
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 3373
                            [post_author] => 5
                            [post_date] => 2021-06-30 16:31:33
                            [post_date_gmt] => 2021-06-30 16:31:33
                            [post_content] => 
                            [post_title] => Gates Foundation - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:17:38
                            [post_modified_gmt] => 2022-10-11 12:17:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3373
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 3333
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:11:59
                            [post_date_gmt] => 2021-06-30 12:11:59
                            [post_content] => 
                            [post_title] => Gates Foundation - CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:17:55
                            [post_modified_gmt] => 2022-10-11 12:17:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3333
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 12574
                            [post_author] => 5
                            [post_date] => 2025-08-20 07:53:01
                            [post_date_gmt] => 2025-08-20 07:53:01
                            [post_content] => 
                            [post_title] => Gates Foundation - CureVac, RNA Rotavirus Vaccine R&D Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-curevac-rna-rotavirus-vaccine-rd-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-20 07:53:01
                            [post_modified_gmt] => 2025-08-20 07:53:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12574
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 5586
                            [post_author] => 5
                            [post_date] => 2022-08-11 09:34:02
                            [post_date_gmt] => 2022-08-11 09:34:02
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:37:27
                            [post_modified_gmt] => 2022-08-11 09:37:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5586
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 5589
                            [post_author] => 5
                            [post_date] => 2022-08-11 09:35:21
                            [post_date_gmt] => 2022-08-11 09:35:21
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:35:21
                            [post_modified_gmt] => 2022-08-11 09:35:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5589
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 6626
                            [post_author] => 5
                            [post_date] => 2022-11-08 11:48:23
                            [post_date_gmt] => 2022-11-08 11:48:23
                            [post_content] => 
                            [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 11:48:23
                            [post_modified_gmt] => 2022-11-08 11:48:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=6626
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 11261
                            [post_author] => 5
                            [post_date] => 2023-09-19 08:31:45
                            [post_date_gmt] => 2023-09-19 08:31:45
                            [post_content] => 
                            [post_title] => Gates Foundation - Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-19 08:31:45
                            [post_modified_gmt] => 2023-09-19 08:31:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11261
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 1392
                            [post_author] => 5
                            [post_date] => 2020-05-30 20:09:57
                            [post_date_gmt] => 2020-05-30 20:09:57
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-sample-terms-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 11:07:43
                            [post_modified_gmt] => 2022-12-16 11:07:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1392
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 12591
                            [post_author] => 5
                            [post_date] => 2025-03-04 07:56:15
                            [post_date_gmt] => 2025-03-04 07:56:15
                            [post_content] => 
                            [post_title] => GOSH Charity Grant Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gosh-charity-grant-terms-and-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-03-04 07:56:15
                            [post_modified_gmt] => 2025-03-04 07:56:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12591
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 1075
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:13:25
                            [post_date_gmt] => 2020-05-21 20:13:25
                            [post_content] => 
                            [post_title] => IMI 1 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-1-model-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-07 11:54:17
                            [post_modified_gmt] => 2024-11-07 11:54:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1075
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 1077
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:15:15
                            [post_date_gmt] => 2020-05-21 20:15:15
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-07 11:54:35
                            [post_modified_gmt] => 2024-11-07 11:54:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1077
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 11692
                            [post_author] => 5
                            [post_date] => 2024-04-08 09:14:55
                            [post_date_gmt] => 2024-04-08 09:14:55
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 09:14:55
                            [post_modified_gmt] => 2024-04-08 09:14:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11692
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 12092
                            [post_author] => 5
                            [post_date] => 2024-10-08 10:45:15
                            [post_date_gmt] => 2024-10-08 10:45:15
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:56:39
                            [post_modified_gmt] => 2024-10-09 14:56:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12092
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 9058
                            [post_author] => 5
                            [post_date] => 2023-03-06 11:20:36
                            [post_date_gmt] => 2023-03-06 11:20:36
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:33:14
                            [post_modified_gmt] => 2023-03-08 11:33:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9058
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 12405
                            [post_author] => 5
                            [post_date] => 2024-12-03 12:07:06
                            [post_date_gmt] => 2024-12-03 12:07:06
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-03 12:07:06
                            [post_modified_gmt] => 2024-12-03 12:07:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12405
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 9074
                            [post_author] => 5
                            [post_date] => 2023-03-07 13:56:00
                            [post_date_gmt] => 2023-03-07 13:56:00
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-16 14:19:29
                            [post_modified_gmt] => 2024-07-16 14:19:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9074
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 11016
                            [post_author] => 5
                            [post_date] => 2023-08-23 06:56:23
                            [post_date_gmt] => 2023-08-23 06:56:23
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 11016
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 09:11:35
                            [post_modified_gmt] => 2023-08-24 09:11:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11016
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 1104
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:42:29
                            [post_date_gmt] => 2020-05-21 20:42:29
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:21:19
                            [post_modified_gmt] => 2022-10-11 12:21:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1104
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 7440
                            [post_author] => 5
                            [post_date] => 2022-12-01 11:18:22
                            [post_date_gmt] => 2022-12-01 11:18:22
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-01 11:18:22
                            [post_modified_gmt] => 2022-12-01 11:18:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=7440
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 11109
                            [post_author] => 5
                            [post_date] => 2023-09-01 06:30:03
                            [post_date_gmt] => 2023-09-01 06:30:03
                            [post_content] => 
                            [post_title] => US Department of Defense - Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 15:45:40
                            [post_modified_gmt] => 2023-09-04 15:45:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11109
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 3776
                            [post_author] => 5
                            [post_date] => 2021-09-09 11:24:04
                            [post_date_gmt] => 2021-09-09 11:24:04
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:12:55
                            [post_modified_gmt] => 2021-09-15 12:12:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3776
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 2732
                            [post_author] => 5
                            [post_date] => 2021-03-23 15:54:07
                            [post_date_gmt] => 2021-03-23 15:54:07
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-statement-of-work-for-rapid-wf10-advanced-research-development-to-large-scale-manufacturing-of-nvx-cov-2373-as-a-vaccine-for-sars-cov-2-coronavirus-under-the-base-agreemen
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:18:39
                            [post_modified_gmt] => 2021-09-15 12:18:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2732
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 2455
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:19:51
                            [post_date_gmt] => 2021-02-25 15:19:51
                            [post_content] => 
                            [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:13:19
                            [post_modified_gmt] => 2021-09-15 12:13:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2455
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 2817
                            [post_author] => 5
                            [post_date] => 2021-04-16 11:58:45
                            [post_date_gmt] => 2021-04-16 11:58:45
                            [post_content] => 
                            [post_title] => US Department of Defense – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-05 07:58:47
                            [post_modified_gmt] => 2024-09-05 07:58:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2817
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 12076
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:24:25
                            [post_date_gmt] => 2024-10-07 14:24:25
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 15:06:03
                            [post_modified_gmt] => 2024-10-07 15:06:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=12076
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 6274
                            [post_author] => 5
                            [post_date] => 2022-10-25 07:10:40
                            [post_date_gmt] => 2022-10-25 07:10:40
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-25 07:11:03
                            [post_modified_gmt] => 2022-10-25 07:11:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=6274
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 11632
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:32:34
                            [post_date_gmt] => 2024-02-19 08:32:34
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:32:34
                            [post_modified_gmt] => 2024-02-19 08:32:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11632
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 45
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 11902
                    [post_author] => 5
                    [post_date] => 2024-08-26 12:25:26
                    [post_date_gmt] => 2024-08-26 12:25:26
                    [post_content] => 
                    [post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-26 12:25:26
                    [post_modified_gmt] => 2024-08-26 12:25:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=agreement&p=11902
                    [menu_order] => 0
                    [post_type] => agreement
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 45
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 1
            [is_search] => 
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => 871908cedb317c9fc2fe54aa249c33d6
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => 
            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

            [query_cache_key:WP_Query:private] => wp_query:070b84f7fb26f9d9968f939e3851be6b
        )

    [provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => issue
                                    [field] => slug
                                    [terms] => Array
                                        (
                                            [0] => roles-responsibilities
                                        )

                                )

                        )

                    [meta_query] => Array
                        (
                            [relation] => OR
                            [0] => Array
                                (
                                    [key] => agreement
                                    [value] => "11902"
                                    [compare] => LIKE
                                )

                            [1] => Array
                                (
                                    [key] => agreement
                                    [value] => "5773"
                                    [compare] => LIKE
                                )

                            [2] => Array
                                (
                                    [key] => agreement
                                    [value] => "2438"
                                    [compare] => LIKE
                                )

                            [3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1040"
                                    [compare] => LIKE
                                )

                            [4] => Array
                                (
                                    [key] => agreement
                                    [value] => "3313"
                                    [compare] => LIKE
                                )

                            [5] => Array
                                (
                                    [key] => agreement
                                    [value] => "2882"
                                    [compare] => LIKE
                                )

                            [6] => Array
                                (
                                    [key] => agreement
                                    [value] => "11914"
                                    [compare] => LIKE
                                )

                            [7] => Array
                                (
                                    [key] => agreement
                                    [value] => "3719"
                                    [compare] => LIKE
                                )

                            [8] => Array
                                (
                                    [key] => agreement
                                    [value] => "12939"
                                    [compare] => LIKE
                                )

                            [9] => Array
                                (
                                    [key] => agreement
                                    [value] => "8049"
                                    [compare] => LIKE
                                )

                            [10] => Array
                                (
                                    [key] => agreement
                                    [value] => "994"
                                    [compare] => LIKE
                                )

                            [11] => Array
                                (
                                    [key] => agreement
                                    [value] => "7560"
                                    [compare] => LIKE
                                )

                            [12] => Array
                                (
                                    [key] => agreement
                                    [value] => "1101"
                                    [compare] => LIKE
                                )

                            [13] => Array
                                (
                                    [key] => agreement
                                    [value] => "12042"
                                    [compare] => LIKE
                                )

                            [14] => Array
                                (
                                    [key] => agreement
                                    [value] => "4678"
                                    [compare] => LIKE
                                )

                            [15] => Array
                                (
                                    [key] => agreement
                                    [value] => "4692"
                                    [compare] => LIKE
                                )

                            [16] => Array
                                (
                                    [key] => agreement
                                    [value] => "12977"
                                    [compare] => LIKE
                                )

                            [17] => Array
                                (
                                    [key] => agreement
                                    [value] => "11819"
                                    [compare] => LIKE
                                )

                            [18] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                )

                            [19] => Array
                                (
                                    [key] => agreement
                                    [value] => "3333"
                                    [compare] => LIKE
                                )

                            [20] => Array
                                (
                                    [key] => agreement
                                    [value] => "12574"
                                    [compare] => LIKE
                                )

                            [21] => Array
                                (
                                    [key] => agreement
                                    [value] => "5586"
                                    [compare] => LIKE
                                )

                            [22] => Array
                                (
                                    [key] => agreement
                                    [value] => "5589"
                                    [compare] => LIKE
                                )

                            [23] => Array
                                (
                                    [key] => agreement
                                    [value] => "6626"
                                    [compare] => LIKE
                                )

                            [24] => Array
                                (
                                    [key] => agreement
                                    [value] => "11261"
                                    [compare] => LIKE
                                )

                            [25] => Array
                                (
                                    [key] => agreement
                                    [value] => "1392"
                                    [compare] => LIKE
                                )

                            [26] => Array
                                (
                                    [key] => agreement
                                    [value] => "12591"
                                    [compare] => LIKE
                                )

                            [27] => Array
                                (
                                    [key] => agreement
                                    [value] => "1075"
                                    [compare] => LIKE
                                )

                            [28] => Array
                                (
                                    [key] => agreement
                                    [value] => "1077"
                                    [compare] => LIKE
                                )

                            [29] => Array
                                (
                                    [key] => agreement
                                    [value] => "11692"
                                    [compare] => LIKE
                                )

                            [30] => Array
                                (
                                    [key] => agreement
                                    [value] => "12092"
                                    [compare] => LIKE
                                )

                            [31] => Array
                                (
                                    [key] => agreement
                                    [value] => "9058"
                                    [compare] => LIKE
                                )

                            [32] => Array
                                (
                                    [key] => agreement
                                    [value] => "12405"
                                    [compare] => LIKE
                                )

                            [33] => Array
                                (
                                    [key] => agreement
                                    [value] => "9074"
                                    [compare] => LIKE
                                )

                            [34] => Array
                                (
                                    [key] => agreement
                                    [value] => "11016"
                                    [compare] => LIKE
                                )

                            [35] => Array
                                (
                                    [key] => agreement
                                    [value] => "1104"
                                    [compare] => LIKE
                                )

                            [36] => Array
                                (
                                    [key] => agreement
                                    [value] => "7440"
                                    [compare] => LIKE
                                )

                            [37] => Array
                                (
                                    [key] => agreement
                                    [value] => "11109"
                                    [compare] => LIKE
                                )

                            [38] => Array
                                (
                                    [key] => agreement
                                    [value] => "3776"
                                    [compare] => LIKE
                                )

                            [39] => Array
                                (
                                    [key] => agreement
                                    [value] => "2732"
                                    [compare] => LIKE
                                )

                            [40] => Array
                                (
                                    [key] => agreement
                                    [value] => "2455"
                                    [compare] => LIKE
                                )

                            [41] => Array
                                (
                                    [key] => agreement
                                    [value] => "2817"
                                    [compare] => LIKE
                                )

                            [42] => Array
                                (
                                    [key] => agreement
                                    [value] => "12076"
                                    [compare] => LIKE
                                )

                            [43] => Array
                                (
                                    [key] => agreement
                                    [value] => "6274"
                                    [compare] => LIKE
                                )

                            [44] => Array
                                (
                                    [key] => agreement
                                    [value] => "11632"
                                    [compare] => LIKE
                                )

                        )

                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => issue
                                    [field] => slug
                                    [terms] => Array
                                        (
                                            [0] => roles-responsibilities
                                        )

                                )

                        )

                    [meta_query] => Array
                        (
                            [relation] => OR
                            [0] => Array
                                (
                                    [key] => agreement
                                    [value] => "11902"
                                    [compare] => LIKE
                                )

                            [1] => Array
                                (
                                    [key] => agreement
                                    [value] => "5773"
                                    [compare] => LIKE
                                )

                            [2] => Array
                                (
                                    [key] => agreement
                                    [value] => "2438"
                                    [compare] => LIKE
                                )

                            [3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1040"
                                    [compare] => LIKE
                                )

                            [4] => Array
                                (
                                    [key] => agreement
                                    [value] => "3313"
                                    [compare] => LIKE
                                )

                            [5] => Array
                                (
                                    [key] => agreement
                                    [value] => "2882"
                                    [compare] => LIKE
                                )

                            [6] => Array
                                (
                                    [key] => agreement
                                    [value] => "11914"
                                    [compare] => LIKE
                                )

                            [7] => Array
                                (
                                    [key] => agreement
                                    [value] => "3719"
                                    [compare] => LIKE
                                )

                            [8] => Array
                                (
                                    [key] => agreement
                                    [value] => "12939"
                                    [compare] => LIKE
                                )

                            [9] => Array
                                (
                                    [key] => agreement
                                    [value] => "8049"
                                    [compare] => LIKE
                                )

                            [10] => Array
                                (
                                    [key] => agreement
                                    [value] => "994"
                                    [compare] => LIKE
                                )

                            [11] => Array
                                (
                                    [key] => agreement
                                    [value] => "7560"
                                    [compare] => LIKE
                                )

                            [12] => Array
                                (
                                    [key] => agreement
                                    [value] => "1101"
                                    [compare] => LIKE
                                )

                            [13] => Array
                                (
                                    [key] => agreement
                                    [value] => "12042"
                                    [compare] => LIKE
                                )

                            [14] => Array
                                (
                                    [key] => agreement
                                    [value] => "4678"
                                    [compare] => LIKE
                                )

                            [15] => Array
                                (
                                    [key] => agreement
                                    [value] => "4692"
                                    [compare] => LIKE
                                )

                            [16] => Array
                                (
                                    [key] => agreement
                                    [value] => "12977"
                                    [compare] => LIKE
                                )

                            [17] => Array
                                (
                                    [key] => agreement
                                    [value] => "11819"
                                    [compare] => LIKE
                                )

                            [18] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                )

                            [19] => Array
                                (
                                    [key] => agreement
                                    [value] => "3333"
                                    [compare] => LIKE
                                )

                            [20] => Array
                                (
                                    [key] => agreement
                                    [value] => "12574"
                                    [compare] => LIKE
                                )

                            [21] => Array
                                (
                                    [key] => agreement
                                    [value] => "5586"
                                    [compare] => LIKE
                                )

                            [22] => Array
                                (
                                    [key] => agreement
                                    [value] => "5589"
                                    [compare] => LIKE
                                )

                            [23] => Array
                                (
                                    [key] => agreement
                                    [value] => "6626"
                                    [compare] => LIKE
                                )

                            [24] => Array
                                (
                                    [key] => agreement
                                    [value] => "11261"
                                    [compare] => LIKE
                                )

                            [25] => Array
                                (
                                    [key] => agreement
                                    [value] => "1392"
                                    [compare] => LIKE
                                )

                            [26] => Array
                                (
                                    [key] => agreement
                                    [value] => "12591"
                                    [compare] => LIKE
                                )

                            [27] => Array
                                (
                                    [key] => agreement
                                    [value] => "1075"
                                    [compare] => LIKE
                                )

                            [28] => Array
                                (
                                    [key] => agreement
                                    [value] => "1077"
                                    [compare] => LIKE
                                )

                            [29] => Array
                                (
                                    [key] => agreement
                                    [value] => "11692"
                                    [compare] => LIKE
                                )

                            [30] => Array
                                (
                                    [key] => agreement
                                    [value] => "12092"
                                    [compare] => LIKE
                                )

                            [31] => Array
                                (
                                    [key] => agreement
                                    [value] => "9058"
                                    [compare] => LIKE
                                )

                            [32] => Array
                                (
                                    [key] => agreement
                                    [value] => "12405"
                                    [compare] => LIKE
                                )

                            [33] => Array
                                (
                                    [key] => agreement
                                    [value] => "9074"
                                    [compare] => LIKE
                                )

                            [34] => Array
                                (
                                    [key] => agreement
                                    [value] => "11016"
                                    [compare] => LIKE
                                )

                            [35] => Array
                                (
                                    [key] => agreement
                                    [value] => "1104"
                                    [compare] => LIKE
                                )

                            [36] => Array
                                (
                                    [key] => agreement
                                    [value] => "7440"
                                    [compare] => LIKE
                                )

                            [37] => Array
                                (
                                    [key] => agreement
                                    [value] => "11109"
                                    [compare] => LIKE
                                )

                            [38] => Array
                                (
                                    [key] => agreement
                                    [value] => "3776"
                                    [compare] => LIKE
                                )

                            [39] => Array
                                (
                                    [key] => agreement
                                    [value] => "2732"
                                    [compare] => LIKE
                                )

                            [40] => Array
                                (
                                    [key] => agreement
                                    [value] => "2455"
                                    [compare] => LIKE
                                )

                            [41] => Array
                                (
                                    [key] => agreement
                                    [value] => "2817"
                                    [compare] => LIKE
                                )

                            [42] => Array
                                (
                                    [key] => agreement
                                    [value] => "12076"
                                    [compare] => LIKE
                                )

                            [43] => Array
                                (
                                    [key] => agreement
                                    [value] => "6274"
                                    [compare] => LIKE
                                )

                            [44] => Array
                                (
                                    [key] => agreement
                                    [value] => "11632"
                                    [compare] => LIKE
                                )

                        )

                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [s] => 
                    [sentence] => 
                    [title] => 
                    [fields] => all
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [ignore_sticky_posts] => 
                    [suppress_filters] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [taxonomy] => issue
                    [term] => roles-responsibilities
                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => issue
                                    [terms] => Array
                                        (
                                            [0] => roles-responsibilities
                                        )

                                    [field] => slug
                                    [operator] => IN
                                    [include_children] => 1
                                )

                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                            [0] => wpry_term_relationships
                        )

                    [queried_terms] => Array
                        (
                            [issue] => Array
                                (
                                    [terms] => Array
                                        (
                                            [0] => roles-responsibilities
                                        )

                                    [field] => slug
                                )

                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                            [0] => Array
                                (
                                    [key] => agreement
                                    [value] => "11902"
                                    [compare] => LIKE
                                )

                            [1] => Array
                                (
                                    [key] => agreement
                                    [value] => "5773"
                                    [compare] => LIKE
                                )

                            [2] => Array
                                (
                                    [key] => agreement
                                    [value] => "2438"
                                    [compare] => LIKE
                                )

                            [3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1040"
                                    [compare] => LIKE
                                )

                            [4] => Array
                                (
                                    [key] => agreement
                                    [value] => "3313"
                                    [compare] => LIKE
                                )

                            [5] => Array
                                (
                                    [key] => agreement
                                    [value] => "2882"
                                    [compare] => LIKE
                                )

                            [6] => Array
                                (
                                    [key] => agreement
                                    [value] => "11914"
                                    [compare] => LIKE
                                )

                            [7] => Array
                                (
                                    [key] => agreement
                                    [value] => "3719"
                                    [compare] => LIKE
                                )

                            [8] => Array
                                (
                                    [key] => agreement
                                    [value] => "12939"
                                    [compare] => LIKE
                                )

                            [9] => Array
                                (
                                    [key] => agreement
                                    [value] => "8049"
                                    [compare] => LIKE
                                )

                            [10] => Array
                                (
                                    [key] => agreement
                                    [value] => "994"
                                    [compare] => LIKE
                                )

                            [11] => Array
                                (
                                    [key] => agreement
                                    [value] => "7560"
                                    [compare] => LIKE
                                )

                            [12] => Array
                                (
                                    [key] => agreement
                                    [value] => "1101"
                                    [compare] => LIKE
                                )

                            [13] => Array
                                (
                                    [key] => agreement
                                    [value] => "12042"
                                    [compare] => LIKE
                                )

                            [14] => Array
                                (
                                    [key] => agreement
                                    [value] => "4678"
                                    [compare] => LIKE
                                )

                            [15] => Array
                                (
                                    [key] => agreement
                                    [value] => "4692"
                                    [compare] => LIKE
                                )

                            [16] => Array
                                (
                                    [key] => agreement
                                    [value] => "12977"
                                    [compare] => LIKE
                                )

                            [17] => Array
                                (
                                    [key] => agreement
                                    [value] => "11819"
                                    [compare] => LIKE
                                )

                            [18] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                )

                            [19] => Array
                                (
                                    [key] => agreement
                                    [value] => "3333"
                                    [compare] => LIKE
                                )

                            [20] => Array
                                (
                                    [key] => agreement
                                    [value] => "12574"
                                    [compare] => LIKE
                                )

                            [21] => Array
                                (
                                    [key] => agreement
                                    [value] => "5586"
                                    [compare] => LIKE
                                )

                            [22] => Array
                                (
                                    [key] => agreement
                                    [value] => "5589"
                                    [compare] => LIKE
                                )

                            [23] => Array
                                (
                                    [key] => agreement
                                    [value] => "6626"
                                    [compare] => LIKE
                                )

                            [24] => Array
                                (
                                    [key] => agreement
                                    [value] => "11261"
                                    [compare] => LIKE
                                )

                            [25] => Array
                                (
                                    [key] => agreement
                                    [value] => "1392"
                                    [compare] => LIKE
                                )

                            [26] => Array
                                (
                                    [key] => agreement
                                    [value] => "12591"
                                    [compare] => LIKE
                                )

                            [27] => Array
                                (
                                    [key] => agreement
                                    [value] => "1075"
                                    [compare] => LIKE
                                )

                            [28] => Array
                                (
                                    [key] => agreement
                                    [value] => "1077"
                                    [compare] => LIKE
                                )

                            [29] => Array
                                (
                                    [key] => agreement
                                    [value] => "11692"
                                    [compare] => LIKE
                                )

                            [30] => Array
                                (
                                    [key] => agreement
                                    [value] => "12092"
                                    [compare] => LIKE
                                )

                            [31] => Array
                                (
                                    [key] => agreement
                                    [value] => "9058"
                                    [compare] => LIKE
                                )

                            [32] => Array
                                (
                                    [key] => agreement
                                    [value] => "12405"
                                    [compare] => LIKE
                                )

                            [33] => Array
                                (
                                    [key] => agreement
                                    [value] => "9074"
                                    [compare] => LIKE
                                )

                            [34] => Array
                                (
                                    [key] => agreement
                                    [value] => "11016"
                                    [compare] => LIKE
                                )

                            [35] => Array
                                (
                                    [key] => agreement
                                    [value] => "1104"
                                    [compare] => LIKE
                                )

                            [36] => Array
                                (
                                    [key] => agreement
                                    [value] => "7440"
                                    [compare] => LIKE
                                )

                            [37] => Array
                                (
                                    [key] => agreement
                                    [value] => "11109"
                                    [compare] => LIKE
                                )

                            [38] => Array
                                (
                                    [key] => agreement
                                    [value] => "3776"
                                    [compare] => LIKE
                                )

                            [39] => Array
                                (
                                    [key] => agreement
                                    [value] => "2732"
                                    [compare] => LIKE
                                )

                            [40] => Array
                                (
                                    [key] => agreement
                                    [value] => "2455"
                                    [compare] => LIKE
                                )

                            [41] => Array
                                (
                                    [key] => agreement
                                    [value] => "2817"
                                    [compare] => LIKE
                                )

                            [42] => Array
                                (
                                    [key] => agreement
                                    [value] => "12076"
                                    [compare] => LIKE
                                )

                            [43] => Array
                                (
                                    [key] => agreement
                                    [value] => "6274"
                                    [compare] => LIKE
                                )

                            [44] => Array
                                (
                                    [key] => agreement
                                    [value] => "11632"
                                    [compare] => LIKE
                                )

                            [relation] => OR
                        )

                    [relation] => OR
                    [meta_table] => wpry_postmeta
                    [meta_id_column] => post_id
                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                    [table_aliases:protected] => Array
                        (
                            [0] => wpry_postmeta
                        )

                    [clauses:protected] => Array
                        (
                            [wpry_postmeta] => Array
                                (
                                    [key] => agreement
                                    [value] => "11902"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-1] => Array
                                (
                                    [key] => agreement
                                    [value] => "5773"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-2] => Array
                                (
                                    [key] => agreement
                                    [value] => "2438"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1040"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-4] => Array
                                (
                                    [key] => agreement
                                    [value] => "3313"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-5] => Array
                                (
                                    [key] => agreement
                                    [value] => "2882"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-6] => Array
                                (
                                    [key] => agreement
                                    [value] => "11914"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-7] => Array
                                (
                                    [key] => agreement
                                    [value] => "3719"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-8] => Array
                                (
                                    [key] => agreement
                                    [value] => "12939"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-9] => Array
                                (
                                    [key] => agreement
                                    [value] => "8049"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-10] => Array
                                (
                                    [key] => agreement
                                    [value] => "994"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-11] => Array
                                (
                                    [key] => agreement
                                    [value] => "7560"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-12] => Array
                                (
                                    [key] => agreement
                                    [value] => "1101"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-13] => Array
                                (
                                    [key] => agreement
                                    [value] => "12042"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-14] => Array
                                (
                                    [key] => agreement
                                    [value] => "4678"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-15] => Array
                                (
                                    [key] => agreement
                                    [value] => "4692"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-16] => Array
                                (
                                    [key] => agreement
                                    [value] => "12977"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-17] => Array
                                (
                                    [key] => agreement
                                    [value] => "11819"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-18] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-19] => Array
                                (
                                    [key] => agreement
                                    [value] => "3333"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-20] => Array
                                (
                                    [key] => agreement
                                    [value] => "12574"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-21] => Array
                                (
                                    [key] => agreement
                                    [value] => "5586"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-22] => Array
                                (
                                    [key] => agreement
                                    [value] => "5589"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-23] => Array
                                (
                                    [key] => agreement
                                    [value] => "6626"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-24] => Array
                                (
                                    [key] => agreement
                                    [value] => "11261"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-25] => Array
                                (
                                    [key] => agreement
                                    [value] => "1392"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-26] => Array
                                (
                                    [key] => agreement
                                    [value] => "12591"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-27] => Array
                                (
                                    [key] => agreement
                                    [value] => "1075"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-28] => Array
                                (
                                    [key] => agreement
                                    [value] => "1077"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-29] => Array
                                (
                                    [key] => agreement
                                    [value] => "11692"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-30] => Array
                                (
                                    [key] => agreement
                                    [value] => "12092"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-31] => Array
                                (
                                    [key] => agreement
                                    [value] => "9058"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-32] => Array
                                (
                                    [key] => agreement
                                    [value] => "12405"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-33] => Array
                                (
                                    [key] => agreement
                                    [value] => "9074"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-34] => Array
                                (
                                    [key] => agreement
                                    [value] => "11016"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-35] => Array
                                (
                                    [key] => agreement
                                    [value] => "1104"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-36] => Array
                                (
                                    [key] => agreement
                                    [value] => "7440"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-37] => Array
                                (
                                    [key] => agreement
                                    [value] => "11109"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-38] => Array
                                (
                                    [key] => agreement
                                    [value] => "3776"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-39] => Array
                                (
                                    [key] => agreement
                                    [value] => "2732"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-40] => Array
                                (
                                    [key] => agreement
                                    [value] => "2455"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-41] => Array
                                (
                                    [key] => agreement
                                    [value] => "2817"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-42] => Array
                                (
                                    [key] => agreement
                                    [value] => "12076"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-43] => Array
                                (
                                    [key] => agreement
                                    [value] => "6274"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-44] => Array
                                (
                                    [key] => agreement
                                    [value] => "11632"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                        )

                    [has_or_relation:protected] => 1
                )

            [date_query] => 
            [request] => SELECT   wpry_posts.*
					 FROM wpry_posts  LEFT JOIN wpry_term_relationships ON (wpry_posts.ID = wpry_term_relationships.object_id) INNER JOIN wpry_postmeta ON ( wpry_posts.ID = wpry_postmeta.post_id )
					 WHERE 1=1  AND ( 
  wpry_term_relationships.term_taxonomy_id IN (278)
) AND ( 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"11902\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"5773\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"2438\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"1040\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"3313\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"2882\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"11914\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"3719\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"12939\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"8049\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"994\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"7560\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"1101\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"12042\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"4678\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"4692\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"12977\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"11819\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"3373\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"3333\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"12574\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"5586\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"5589\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"6626\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"11261\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"1392\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"12591\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"1075\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"1077\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"11692\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"12092\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"9058\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"12405\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"9074\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"11016\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"1104\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"7440\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"11109\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"3776\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"2732\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"2455\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"2817\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"12076\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"6274\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}\"11632\"{5034fdf51a8e93b6335295b40514a744a0632ce7a77e1b5a950e93ad721e165c}' )
) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
					 GROUP BY wpry_posts.ID
					 ORDER BY wpry_posts.post_date DESC
					 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 12584
                            [post_author] => 5
                            [post_date] => 2025-08-20 07:37:46
                            [post_date_gmt] => 2025-08-20 07:37:46
                            [post_content] => 
                            [post_title] => Gates Foundation - CureVac, RNA Rotavirus Vaccine R&D Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-curevac-rna-rotavirus-vaccine-rd-collaboration-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-20 07:38:33
                            [post_modified_gmt] => 2025-08-20 07:38:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12584
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 12962
                            [post_author] => 5
                            [post_date] => 2025-08-13 11:42:16
                            [post_date_gmt] => 2025-08-13 11:42:16
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-08-20 08:43:11
                            [post_modified_gmt] => 2025-08-20 08:43:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12962
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 12601
                            [post_author] => 5
                            [post_date] => 2025-03-04 09:52:01
                            [post_date_gmt] => 2025-03-04 09:52:01
                            [post_content] => 
                            [post_title] => GOSH Charity Grant Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gosh-charity-grant-terms-and-conditions-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2025-03-04 09:52:01
                            [post_modified_gmt] => 2025-03-04 09:52:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12601
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 12414
                            [post_author] => 5
                            [post_date] => 2024-12-05 12:37:47
                            [post_date_gmt] => 2024-12-05 12:37:47
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-12-05 15:43:28
                            [post_modified_gmt] => 2024-12-05 15:43:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12414
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 12104
                            [post_author] => 5
                            [post_date] => 2024-10-09 14:58:53
                            [post_date_gmt] => 2024-10-09 14:58:53
                            [post_content] => 
                            [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-09 14:58:53
                            [post_modified_gmt] => 2024-10-09 14:58:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12104
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 12086
                            [post_author] => 5
                            [post_date] => 2024-10-07 14:09:43
                            [post_date_gmt] => 2024-10-07 14:09:43
                            [post_content] => 
                            [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-07 14:35:44
                            [post_modified_gmt] => 2024-10-07 14:35:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12086
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 12051
                            [post_author] => 5
                            [post_date] => 2024-09-12 12:37:11
                            [post_date_gmt] => 2024-09-12 12:37:11
                            [post_content] => 
                            [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-12 12:37:11
                            [post_modified_gmt] => 2024-09-12 12:37:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 11998
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:54
                            [post_date_gmt] => 2024-09-02 09:17:54
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 10:48:33
                            [post_modified_gmt] => 2024-09-02 10:48:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11998
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 11834
                            [post_author] => 5
                            [post_date] => 2024-07-15 15:09:41
                            [post_date_gmt] => 2024-07-15 15:09:41
                            [post_content] => 
                            [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-15 15:10:44
                            [post_modified_gmt] => 2024-07-15 15:10:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11834
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 11701
                            [post_author] => 5
                            [post_date] => 2024-04-08 10:08:21
                            [post_date_gmt] => 2024-04-08 10:08:21
                            [post_content] => 
                            [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 11:21:00
                            [post_modified_gmt] => 2024-04-08 11:21:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11701
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 11646
                            [post_author] => 5
                            [post_date] => 2024-02-19 08:45:09
                            [post_date_gmt] => 2024-02-19 08:45:09
                            [post_content] => 
                            [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-standard-grant-terms-conditions-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-02-19 08:51:59
                            [post_modified_gmt] => 2024-02-19 08:51:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11646
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 11339
                            [post_author] => 5
                            [post_date] => 2023-09-26 14:15:18
                            [post_date_gmt] => 2023-09-26 14:15:18
                            [post_content] => 
                            [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-26 14:15:18
                            [post_modified_gmt] => 2023-09-26 14:15:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11339
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 11137
                            [post_author] => 5
                            [post_date] => 2023-09-05 06:29:43
                            [post_date_gmt] => 2023-09-05 06:29:43
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 06:29:43
                            [post_modified_gmt] => 2023-09-05 06:29:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11137
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 11023
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:10:08
                            [post_date_gmt] => 2023-08-24 08:10:08
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:10:08
                            [post_modified_gmt] => 2023-08-24 08:10:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11023
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 9083
                            [post_author] => 5
                            [post_date] => 2023-03-08 09:45:42
                            [post_date_gmt] => 2023-03-08 09:45:42
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:41:43
                            [post_modified_gmt] => 2024-09-20 12:41:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9083
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 9068
                            [post_author] => 5
                            [post_date] => 2023-03-06 18:20:18
                            [post_date_gmt] => 2023-03-06 18:20:18
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-20 12:19:36
                            [post_modified_gmt] => 2024-09-20 12:19:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9068
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 8479
                            [post_author] => 5
                            [post_date] => 2023-01-17 17:35:45
                            [post_date_gmt] => 2023-01-17 17:35:45
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 09:22:09
                            [post_modified_gmt] => 2023-07-11 09:22:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8479
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 8143
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:10:19
                            [post_date_gmt] => 2022-12-12 11:10:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:12:03
                            [post_modified_gmt] => 2024-11-18 15:12:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8143
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 7570
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:44:09
                            [post_date_gmt] => 2022-12-07 16:44:09
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:04:49
                            [post_modified_gmt] => 2024-04-09 08:04:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7570
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 7468
                            [post_author] => 5
                            [post_date] => 2022-12-05 12:56:35
                            [post_date_gmt] => 2022-12-05 12:56:35
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 09:23:05
                            [post_modified_gmt] => 2024-10-30 09:23:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7468
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 6630
                            [post_author] => 5
                            [post_date] => 2022-11-08 15:22:11
                            [post_date_gmt] => 2022-11-08 15:22:11
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 08:56:26
                            [post_modified_gmt] => 2023-07-11 08:56:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6630
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 6283
                            [post_author] => 5
                            [post_date] => 2022-10-25 14:33:12
                            [post_date_gmt] => 2022-10-25 14:33:12
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 13:09:22
                            [post_modified_gmt] => 2023-10-17 13:09:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6283
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 5812
                            [post_author] => 5
                            [post_date] => 2022-10-05 14:34:35
                            [post_date_gmt] => 2022-10-05 14:34:35
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 09:45:00
                            [post_modified_gmt] => 2024-01-11 09:45:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5812
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 5624
                            [post_author] => 5
                            [post_date] => 2022-08-17 08:56:52
                            [post_date_gmt] => 2022-08-17 08:56:52
                            [post_content] => 
                            [post_title] => CARB-X Portfolio Company Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 13:47:22
                            [post_modified_gmt] => 2024-04-10 13:47:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5624
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 4857
                            [post_author] => 5
                            [post_date] => 2022-06-02 10:16:52
                            [post_date_gmt] => 2022-06-02 10:16:52
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:09:51
                            [post_modified_gmt] => 2023-11-10 15:09:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4857
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 4704
                            [post_author] => 5
                            [post_date] => 2022-04-26 15:08:03
                            [post_date_gmt] => 2022-04-26 15:08:03
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-07-23 14:25:04
                            [post_modified_gmt] => 2024-07-23 14:25:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4704
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 4200
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:13:29
                            [post_date_gmt] => 2022-02-28 13:13:29
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:54:49
                            [post_modified_gmt] => 2023-06-22 13:54:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 4061
                            [post_author] => 5
                            [post_date] => 2022-01-07 09:46:42
                            [post_date_gmt] => 2022-01-07 09:46:42
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-23 10:24:42
                            [post_modified_gmt] => 2024-09-23 10:24:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4061
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 3792
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:23:13
                            [post_date_gmt] => 2021-09-09 14:23:13
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-30 10:07:03
                            [post_modified_gmt] => 2024-10-30 10:07:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3792
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 3756
                            [post_author] => 5
                            [post_date] => 2021-08-25 08:10:37
                            [post_date_gmt] => 2021-08-25 08:10:37
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 12:23:27
                            [post_modified_gmt] => 2023-06-26 12:23:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3756
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 3323
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:15:16
                            [post_date_gmt] => 2021-06-30 11:15:16
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 10:10:57
                            [post_modified_gmt] => 2024-01-11 10:10:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3323
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 2467
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:15
                            [post_date_gmt] => 2021-02-25 15:20:15
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:32:07
                            [post_modified_gmt] => 2023-08-14 08:32:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 2444
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:27:20
                            [post_date_gmt] => 2021-01-19 09:27:20
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:42:15
                            [post_modified_gmt] => 2023-06-20 10:42:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 33
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 12584
                    [post_author] => 5
                    [post_date] => 2025-08-20 07:37:46
                    [post_date_gmt] => 2025-08-20 07:37:46
                    [post_content] => 
                    [post_title] => Gates Foundation - CureVac, RNA Rotavirus Vaccine R&D Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-curevac-rna-rotavirus-vaccine-rd-collaboration-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-20 07:38:33
                    [post_modified_gmt] => 2025-08-20 07:38:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12584
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 33
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 1
            [is_search] => 
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => f2a698db5ed870af022423c6f95c6c6a
            [query_vars_changed:WP_Query:private] => 
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => 
            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

            [query_cache_key:WP_Query:private] => wp_query:20a76d2a95a8703a4cec31af0c0daf33
        )

    [text_agreement_q_rslts] => 
    [text_provision_q_rslts] => 
    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 12584
                    [post_author] => 5
                    [post_date] => 2025-08-20 07:37:46
                    [post_date_gmt] => 2025-08-20 07:37:46
                    [post_content] => 
                    [post_title] => Gates Foundation - CureVac, RNA Rotavirus Vaccine R&D Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-curevac-rna-rotavirus-vaccine-rd-collaboration-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-20 07:38:33
                    [post_modified_gmt] => 2025-08-20 07:38:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12584
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 12962
                    [post_author] => 5
                    [post_date] => 2025-08-13 11:42:16
                    [post_date_gmt] => 2025-08-13 11:42:16
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-08-20 08:43:11
                    [post_modified_gmt] => 2025-08-20 08:43:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12962
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 12601
                    [post_author] => 5
                    [post_date] => 2025-03-04 09:52:01
                    [post_date_gmt] => 2025-03-04 09:52:01
                    [post_content] => 
                    [post_title] => GOSH Charity Grant Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gosh-charity-grant-terms-and-conditions-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-03-04 09:52:01
                    [post_modified_gmt] => 2025-03-04 09:52:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12601
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 12414
                    [post_author] => 5
                    [post_date] => 2024-12-05 12:37:47
                    [post_date_gmt] => 2024-12-05 12:37:47
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, RSV mRNA-Based Vaccine, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-rsv-mrna-based-vaccine-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-12-05 15:43:28
                    [post_modified_gmt] => 2024-12-05 15:43:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12414
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 12104
                    [post_author] => 5
                    [post_date] => 2024-10-09 14:58:53
                    [post_date_gmt] => 2024-10-09 14:58:53
                    [post_content] => 
                    [post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-09 14:58:53
                    [post_modified_gmt] => 2024-10-09 14:58:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12104
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 12086
                    [post_author] => 5
                    [post_date] => 2024-10-07 14:09:43
                    [post_date_gmt] => 2024-10-07 14:09:43
                    [post_content] => 
                    [post_title] => Wellcome Trust - Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-alto-neuroscience-bipolar-depression-therapeutic-convertible-loan-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-07 14:35:44
                    [post_modified_gmt] => 2024-10-07 14:35:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12086
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 12051
                    [post_author] => 5
                    [post_date] => 2024-09-12 12:37:11
                    [post_date_gmt] => 2024-09-12 12:37:11
                    [post_content] => 
                    [post_title] => Gates Foundation - Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies - ACTs), Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-amyris-inc-malaria-therapeutic-artemisinin-based-combination-therapies-acts-letter-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-12 12:37:11
                    [post_modified_gmt] => 2024-09-12 12:37:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12051
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 11998
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:54
                    [post_date_gmt] => 2024-09-02 09:17:54
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 10:48:33
                    [post_modified_gmt] => 2024-09-02 10:48:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11998
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 11834
                    [post_author] => 5
                    [post_date] => 2024-07-15 15:09:41
                    [post_date_gmt] => 2024-07-15 15:09:41
                    [post_content] => 
                    [post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-15 15:10:44
                    [post_modified_gmt] => 2024-07-15 15:10:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11834
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 11701
                    [post_author] => 5
                    [post_date] => 2024-04-08 10:08:21
                    [post_date_gmt] => 2024-04-08 10:08:21
                    [post_content] => 
                    [post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-08 11:21:00
                    [post_modified_gmt] => 2024-04-08 11:21:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11701
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 11646
                    [post_author] => 5
                    [post_date] => 2024-02-19 08:45:09
                    [post_date_gmt] => 2024-02-19 08:45:09
                    [post_content] => 
                    [post_title] => Wellcome Trust Standard Grant Terms & Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-standard-grant-terms-conditions-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-02-19 08:51:59
                    [post_modified_gmt] => 2024-02-19 08:51:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11646
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 11339
                    [post_author] => 5
                    [post_date] => 2023-09-26 14:15:18
                    [post_date_gmt] => 2023-09-26 14:15:18
                    [post_content] => 
                    [post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-26 14:15:18
                    [post_modified_gmt] => 2023-09-26 14:15:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11339
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 11137
                    [post_author] => 5
                    [post_date] => 2023-09-05 06:29:43
                    [post_date_gmt] => 2023-09-05 06:29:43
                    [post_content] => 
                    [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-05 06:29:43
                    [post_modified_gmt] => 2023-09-05 06:29:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11137
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 11023
                    [post_author] => 5
                    [post_date] => 2023-08-24 08:10:08
                    [post_date_gmt] => 2023-08-24 08:10:08
                    [post_content] => 
                    [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-24 08:10:08
                    [post_modified_gmt] => 2023-08-24 08:10:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11023
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 9083
                    [post_author] => 5
                    [post_date] => 2023-03-08 09:45:42
                    [post_date_gmt] => 2023-03-08 09:45:42
                    [post_content] => 
                    [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:41:43
                    [post_modified_gmt] => 2024-09-20 12:41:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9083
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 9068
                    [post_author] => 5
                    [post_date] => 2023-03-06 18:20:18
                    [post_date_gmt] => 2023-03-06 18:20:18
                    [post_content] => 
                    [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-20 12:19:36
                    [post_modified_gmt] => 2024-09-20 12:19:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=9068
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 8479
                    [post_author] => 5
                    [post_date] => 2023-01-17 17:35:45
                    [post_date_gmt] => 2023-01-17 17:35:45
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 09:22:09
                    [post_modified_gmt] => 2023-07-11 09:22:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8479
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 8143
                    [post_author] => 5
                    [post_date] => 2022-12-12 11:10:19
                    [post_date_gmt] => 2022-12-12 11:10:19
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:12:03
                    [post_modified_gmt] => 2024-11-18 15:12:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8143
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 7570
                    [post_author] => 5
                    [post_date] => 2022-12-07 16:44:09
                    [post_date_gmt] => 2022-12-07 16:44:09
                    [post_content] => 
                    [post_title] => FIND Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => find-sample-funding-terms-and-conditions-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-09 08:04:49
                    [post_modified_gmt] => 2024-04-09 08:04:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7570
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 7468
                    [post_author] => 5
                    [post_date] => 2022-12-05 12:56:35
                    [post_date_gmt] => 2022-12-05 12:56:35
                    [post_content] => 
                    [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => unitaidexplore-sample-funding-terms-and-conditions-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 09:23:05
                    [post_modified_gmt] => 2024-10-30 09:23:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=7468
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 6630
                    [post_author] => 5
                    [post_date] => 2022-11-08 15:22:11
                    [post_date_gmt] => 2022-11-08 15:22:11
                    [post_content] => 
                    [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 08:56:26
                    [post_modified_gmt] => 2023-07-11 08:56:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6630
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 6283
                    [post_author] => 5
                    [post_date] => 2022-10-25 14:33:12
                    [post_date_gmt] => 2022-10-25 14:33:12
                    [post_content] => 
                    [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-17 13:09:22
                    [post_modified_gmt] => 2023-10-17 13:09:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=6283
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 5812
                    [post_author] => 5
                    [post_date] => 2022-10-05 14:34:35
                    [post_date_gmt] => 2022-10-05 14:34:35
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 09:45:00
                    [post_modified_gmt] => 2024-01-11 09:45:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5812
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 5624
                    [post_author] => 5
                    [post_date] => 2022-08-17 08:56:52
                    [post_date_gmt] => 2022-08-17 08:56:52
                    [post_content] => 
                    [post_title] => CARB-X Portfolio Company Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-10 13:47:22
                    [post_modified_gmt] => 2024-04-10 13:47:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5624
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 4857
                    [post_author] => 5
                    [post_date] => 2022-06-02 10:16:52
                    [post_date_gmt] => 2022-06-02 10:16:52
                    [post_content] => 
                    [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 15:09:51
                    [post_modified_gmt] => 2023-11-10 15:09:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4857
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 4704
                    [post_author] => 5
                    [post_date] => 2022-04-26 15:08:03
                    [post_date_gmt] => 2022-04-26 15:08:03
                    [post_content] => 
                    [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-07-23 14:25:04
                    [post_modified_gmt] => 2024-07-23 14:25:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4704
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 4200
                    [post_author] => 5
                    [post_date] => 2022-02-28 13:13:29
                    [post_date_gmt] => 2022-02-28 13:13:29
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:54:49
                    [post_modified_gmt] => 2023-06-22 13:54:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 4061
                    [post_author] => 5
                    [post_date] => 2022-01-07 09:46:42
                    [post_date_gmt] => 2022-01-07 09:46:42
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => path-aridis-rotavirus-vaccine-development-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-23 10:24:42
                    [post_modified_gmt] => 2024-09-23 10:24:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4061
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 3792
                    [post_author] => 5
                    [post_date] => 2021-09-09 14:23:13
                    [post_date_gmt] => 2021-09-09 14:23:13
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-30 10:07:03
                    [post_modified_gmt] => 2024-10-30 10:07:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3792
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 3756
                    [post_author] => 5
                    [post_date] => 2021-08-25 08:10:37
                    [post_date_gmt] => 2021-08-25 08:10:37
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 12:23:27
                    [post_modified_gmt] => 2023-06-26 12:23:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3756
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 3323
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:15:16
                    [post_date_gmt] => 2021-06-30 11:15:16
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 10:10:57
                    [post_modified_gmt] => 2024-01-11 10:10:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3323
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 2467
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:20:15
                    [post_date_gmt] => 2021-02-25 15:20:15
                    [post_content] => 
                    [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-14 08:32:07
                    [post_modified_gmt] => 2023-08-14 08:32:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 2444
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:27:20
                    [post_date_gmt] => 2021-01-19 09:27:20
                    [post_content] => 
                    [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 10:42:15
                    [post_modified_gmt] => 2023-06-20 10:42:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [invalid_get] => 
    [is_text_search] => 
    [has_agreement_filters] => 1
    [has_any_agreement_filter] => Array
        (
            [agreement-type] => 
        )

    [found_agreements] => 1
    [has_provision_filters] => 1
    [found_provisions] => 1
    [lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
    [lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
    [lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
    [lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
    [lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
    [lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
    [lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
    [issues_by_id:GHIAA2019\MapguideSearch:private] => Array
        (
            [101] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
 	How should equitable or global access be defined?
 	Should the developer be required to comply with an equitable access policy?
 	Should the developer be required to establish an access plan?

                    [parent] => 46
                    [count] => 64
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [100] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 57
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [66] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 18
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [53] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [371] => WP_Term Object
                (
                    [term_id] => 371
                    [name] => Clinical trial conduct
                    [slug] => clinical-trial-conduct
                    [term_group] => 0
                    [term_taxonomy_id] => 371
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [84] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
 	What is the scope of confidential information?
 	What are the obligations of the parties to protect confidential information?
 	Are there any exceptions to the confidentiality obligations?
 	Are the parties permitted to make public announcements related to the project?
 	Can the parties use each other’s name and logo for general marketing materials?

                    [parent] => 49
                    [count] => 123
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [271] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [72] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effects of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 106
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [281] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
 	Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
 	What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
 	Should related license grants vest upon execution of the agreement, or at a later stage in development?
 	Should there be an escrow requirement?
 	Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?

                    [parent] => 46
                    [count] => 64
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [46] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [278] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Governance
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
 	Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
 	Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
 	Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
 	What are the resolution mechanisms for disputes related to the agreement?
 	Are there any requirements for policies or procedures to manage potential conflicts of interest?

                    [parent] => 53
                    [count] => 109
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [80] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification & liability
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
 	What occurrences could result in a liability claim against which one party will indemnify the other?
 	Are there any circumstances under which one party will not indemnify the other?
 	What is the process for managing liability claims?
 	Are there government or other types of indemnification schemes?
 	Is there any limitation or monetary cap on each party’s liabilities under the agreement?

                    [parent] => 50
                    [count] => 120
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [257] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
 	What financial and project progress information must be shared between the parties?
 	What is the required timeline for sharing information?
 	How is the receiving party permitted to use the information received?
 	Do the parties have the right to verify the information reported?

                    [parent] => 49
                    [count] => 114
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [109] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 76
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [48] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [50] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [88] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => License grants
                    [slug] => license-grants
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
 	Are any licenses granted for the use of background or foreground intellectual property?
 	What is the scope of the licensed intellectual property?
 	What is the territory of the license?
 	Is the license exclusive or non-exclusive?
 	Are there any restrictions on the use of the licensed intellectual property?
 	Are there any specific obligations to exploit the licensed intellectual property?
 	Can the licensee grant sublicenses to third parties?
 	Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)

                    [parent] => 48
                    [count] => 115
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [87] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of IP
                    [slug] => ownership-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 87
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [70] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => What is the payment structure under this agreement? 
What are the mechanisms to limit exposure to additional payments or expenses?
                    [parent] => 53
                    [count] => 98
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [102] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [268] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 47
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [49] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Protecting & sharing information
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [90] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 91
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [290] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Publication of results
                    [slug] => publication-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
                    [parent] => 49
                    [count] => 72
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [372] => WP_Term Object
                (
                    [term_id] => 372
                    [name] => Quality management
                    [slug] => quality-management
                    [term_group] => 0
                    [term_taxonomy_id] => 372
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 47
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [56] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 62
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [81] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => Should the parties make any warranties, and if so, what is the scope?
                    [parent] => 50
                    [count] => 108
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [86] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
                    [parent] => 49
                    [count] => 49
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [52] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => Term

 	What is the term of the agreement? Is it tied to the timeline of the project or license grants?

Termination

 	Under what circumstances may a party terminate or withdraw from the agreement?

Effects of Termination

 	What are the effects of termination or withdrawal by a party?

                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [76] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 107
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [74] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 112
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [282] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
 	How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
 	Should the developer be required to apply for regulatory approval in priority access markets?
 	Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
 	Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
 	Should the agreement include any anti-diversion provisions?

                    [parent] => 46
                    [count] => 69
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

        )

    [issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
        (
            [equitable-access] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
 	How should equitable or global access be defined?
 	Should the developer be required to comply with an equitable access policy?
 	Should the developer be required to establish an access plan?

                    [parent] => 46
                    [count] => 64
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [pricing] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 57
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [benefit-revenue-sharing] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 18
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [business-model] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [clinical-trial-conduct] => WP_Term Object
                (
                    [term_id] => 371
                    [name] => Clinical trial conduct
                    [slug] => clinical-trial-conduct
                    [term_group] => 0
                    [term_taxonomy_id] => 371
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [confidentiality] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
 	What is the scope of confidential information?
 	What are the obligations of the parties to protect confidential information?
 	Are there any exceptions to the confidentiality obligations?
 	Are the parties permitted to make public announcements related to the project?
 	Can the parties use each other’s name and logo for general marketing materials?

                    [parent] => 49
                    [count] => 123
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [donation] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [effect-of-termination] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effects of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 106
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [ensuring-continuity] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
 	Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
 	What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
 	Should related license grants vest upon execution of the agreement, or at a later stage in development?
 	Should there be an escrow requirement?
 	Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?

                    [parent] => 46
                    [count] => 64
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [access-to-medicines] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [roles-responsibilities] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Governance
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
 	Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
 	Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
 	Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
 	What are the resolution mechanisms for disputes related to the agreement?
 	Are there any requirements for policies or procedures to manage potential conflicts of interest?

                    [parent] => 53
                    [count] => 109
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [indemnity] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification & liability
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
 	What occurrences could result in a liability claim against which one party will indemnify the other?
 	Are there any circumstances under which one party will not indemnify the other?
 	What is the process for managing liability claims?
 	Are there government or other types of indemnification schemes?
 	Is there any limitation or monetary cap on each party’s liabilities under the agreement?

                    [parent] => 50
                    [count] => 120
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [information-sharing-information-sharing] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
 	What financial and project progress information must be shared between the parties?
 	What is the required timeline for sharing information?
 	How is the receiving party permitted to use the information received?
 	Do the parties have the right to verify the information reported?

                    [parent] => 49
                    [count] => 114
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [insurance] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 76
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [ip-ownership] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [liability] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [license-grants] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => License grants
                    [slug] => license-grants
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
 	Are any licenses granted for the use of background or foreground intellectual property?
 	What is the scope of the licensed intellectual property?
 	What is the territory of the license?
 	Is the license exclusive or non-exclusive?
 	Are there any restrictions on the use of the licensed intellectual property?
 	Are there any specific obligations to exploit the licensed intellectual property?
 	Can the licensee grant sublicenses to third parties?
 	Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)

                    [parent] => 48
                    [count] => 115
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [ownership-ip] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of IP
                    [slug] => ownership-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 87
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [royalties-and-payments] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => What is the payment structure under this agreement? 
What are the mechanisms to limit exposure to additional payments or expenses?
                    [parent] => 53
                    [count] => 98
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [outbreak-preparedness] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [supply-purchase-of-products] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 47
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [information-sharing] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Protecting & sharing information
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [protection-results] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 91
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [publication-of-results] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Publication of results
                    [slug] => publication-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
                    [parent] => 49
                    [count] => 72
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [quality-management] => WP_Term Object
                (
                    [term_id] => 372
                    [name] => Quality management
                    [slug] => quality-management
                    [term_group] => 0
                    [term_taxonomy_id] => 372
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 47
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [regulatory-strategy] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 62
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [warranties] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => Should the parties make any warranties, and if so, what is the scope?
                    [parent] => 50
                    [count] => 108
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [technology-transfer] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
                    [parent] => 49
                    [count] => 49
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [term-and-termination] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => Term

 	What is the term of the agreement? Is it tied to the timeline of the project or license grants?

Termination

 	Under what circumstances may a party terminate or withdraw from the agreement?

Effects of Termination

 	What are the effects of termination or withdrawal by a party?

                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [term-of-agreement] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 107
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [termination-and-withdrawal] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 112
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [territory-access-commitments] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
 	How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
 	Should the developer be required to apply for regulatory approval in priority access markets?
 	Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
 	Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
 	Should the agreement include any anti-diversion provisions?

                    [parent] => 46
                    [count] => 69
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

        )

    [filter_issues:GHIAA2019\MapguideSearch:private] => Array
        (
            [0] => roles-responsibilities
        )

)